James Percy Daniels

James Percy Daniels

Auto-generated profile, based on publicly available information

James Percy Daniels

Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JDJames Percy Daniels
James Percy Daniels
SFStephen J. Freedland
Stephen J. Freedland
GGGillian Gresham
Gillian Gresham
Obesity tends to fan the flames of cancer in multiple organs by way of increasing incidence, promoting progression, and decreasing survival ( 1). With respect to prostate cancer, obesity is often tied to an increased risk of mortality and advanced disease, though the last notion is still debated. Questions remain about what causes the association between obesity and advanced prostate cancer; whether obesity propagates a molecular mechanism that drives aggressive prostate cancer; or whether obesity leads to delayed diagnoses that are left unchecked, resulting in patients ultimately presenting with more advanced disease. Prostate-specific antigen (PSA)–based prostate cancer screening has certainly saved many lives, but it remains controversial and possibly underutilized because of concerns about overdiagnosis and overtreatment (ie, the “harms” from widespread screening). Although some research suggests that obese patients are more likely to undergo PSA screening, we also know that PSA levels from people with a higher body mass index (BMI) are diluted, giving them a false sense of security ( 2). All this begs the question: if annual prostate cancer screening were universal, would prostate cancer still be associated with a higher risk of advanced prostate cancer and related mortality? In this issue of the Journal, Hurwitz and colleagues ( 3) seek to answer this question using a unique study population.

1 January 2024 in Journal of Urology
Verified
Journal Article
Closed access
JDJames P. Daniels
James P. Daniels
JMJames Mirocha
James Mirocha
MAMichie Adjei
Michie Adjei
DMDaniel Moreira
Daniel Moreira
SFStephen J. Freedland
Stephen J. Freedland
Though the pathogenesis of benign prostatic hyperplasia is unclear, it was previously believed that increasing androgen levels contributed, though not all data support this idea. We tested if elevated serum testosterone or dihydrotestosterone were risk factors for lower urinary tract symptoms incidence in asymptomatic men and for lower urinary tract symptoms progression in symptomatic men. A post hoc analysis of REDUCE was performed in 3009 asymptomatic men and in 2145 symptomatic men. REDUCE was a randomized trial of dutasteride for prostate cancer prevention in men with an elevated prostate-specific antigen and negative prestudy biopsy. We estimated multivariable adjusted hazard ratios and 95% confidence intervals using Cox models to test the association between quintiles of serum testosterone and dihydrotestosterone at baseline and lower urinary tract symptoms incidence and progression and tested for interaction by treatment arm (dutasteride vs placebo). In asymptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms incidence (P = .9, P = .4). In symptomatic men, there was no evidence serum testosterone or dihydrotestosterone were related to lower urinary tract symptoms progression (P = .9, P = .7). Results were similar in both placebo and dutasteride arms (all P interaction ≥ .3). In REDUCE, higher serum testosterone and higher serum dihydrotestosterone were not associated with either lower urinary tract symptoms incidence in asymptomatic men or lower urinary tract symptoms progression in symptomatic men. These data do not support the hypothesis that serum androgens in middle-aged men are associated with lower urinary tract symptoms.

8 July 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
JDJames P. Daniels
James P. Daniels
DPDevin N. Patel
Devin N. Patel
GGGloria Cecilia Galvan
Gloria Cecilia Galvan
NFNadine A. Friedrich
Nadine A. Friedrich
SDSanjay Das
Sanjay Das
SFStephen J. Freedland
Stephen J. Freedland
Understanding patient interest among surgical options is challenging. We used Google Trends to analyze interest in benign prostatic hyperplasia (BPH) surgeries recommended for prostate volumes <80 cc. Google Trends was queried with five BPH surgeries. Final rank of search terms was TURP, UroLift, Rezum, Aquablation, and Greenlight. Google Trends can be an effective tool for evaluating public interest trends in BPH surgery.

8 September 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
SDSanjay Das
Sanjay Das
NFNadine A. Friedrich
Nadine A. Friedrich
JDJames Daniels
James Daniels
GGG. Cecilia Galvan
G. Cecilia Galvan
Jun GongJun Gong
Jun Gong
SFStephen J. Freedland
Stephen J. Freedland

2 February 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
GGGloria Cecilia Galván
Gloria Cecilia Galván
SDSanjay Das
Sanjay Das
JDJames P. Daniels
James P. Daniels
NFNadine A. Friedrich
Nadine A. Friedrich
SFStephen J. Freedland
Stephen J. Freedland

2 February 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
GGGloria Cecilia Galván
Gloria Cecilia Galván
JDJames P. Daniels
James P. Daniels
NFNadine A. Friedrich
Nadine A. Friedrich
SDSanjay Das
Sanjay Das
SFStephen J. Freedland
Stephen J. Freedland